Parkinson disease study now enrolling

http://www.bcm.edu/news/item.cfm?newsID=2997

RSS icon HOUSTON -- (November 2, 2010) -- Enrollment has begun in a new double-blind Phase 2b study evaluating CERE-120 in Parkinson's disease patients. Baylor College of Medicine is one of eight clinical sites enrolling along with 11 major medical centers across the country.

CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons in the hopes it will restore function and protect brain cells from further damage.

More Information:
PDtrials.org
Clinical Trials.gov

Following is a List of Participating Sites:

Alabama
University of Alabama, Birmingham
Rebecca McMurray
rmcmurr@uab.edu
Phone: (205) 996-4034
Birmingham, AL
USA

California
Stanford School of Medicine
Maria Coburn
mcoburn@stanford.edu
Phone: (650) 723-5575
Palo Alto, CA
USA

University of California, San Francisco
Robin Taylor
robin.taylor@ucsf.edu
Phone: (415) 353-1555
San Francisco, CA
USA

Georgia
Emory University Hospital
Mary Louise Weeks
mmusant@emory.edu
Phone: (404) 728-4982
Atlanta, GA
USA

Illinois
Rush University Medical Center
Jeana Jaglin
Jean_A_Jaglin@rush.edu
Phone: (312) 563-2900
Chicago, IL
USA

North Carolina
Duke University
Lisa Gauger
lisa.gauger@duke.edu
Phone: (919) 668-1538
Durham, NC
USA

New York
Columbia University Medical Center
Linda Winfield
lmw4@mail.cumc.columbia.edu
Phone: (212) 305-0549
New York, NY
USA

Mt. Sinai Medical Center
Ricardo Renvill
ricardo.renvill@mssm.edu
Phone: (212) 461-4633
New York, NY
USA

Beth Israel Medical Center
Rabhi Kashouty
rkashouty@chpnet.org
Phone: (212) 844-6571
New York, NY
USA

Pennsylvania
University of Pennsylvania
Heather Maccarone
heather.maccarone@pahosp.com
Phone: (215) 829-7181
Philadelphia, PA
USA

Texas
Primary Contact at Ceregene
Ceregene, Inc.
Joao Siffert, M.D. — Chief Medical Officer
jsiffert@ceregene.com
Phone: (858) 458-8890